Telix Pharmaceuticals

Telix is a biopharmaceutical company at the commercialization stage, focusing on the development and commercialization of therapeutic and diagnostic ("theranostic") radiopharmaceuticals. Telix has a broad product portfolio in uro-oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning, supported by a robust global supply, manufacturing, and distribution network. Telix’s prostate cancer imaging agent has received global regulatory approvals from Australia's Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada, with 18 clinical trials currently underway worldwide.